Jin Medical Executes 1-for-20 Reverse Split Reducing Class A to 6.83M and Class B to 1M
Jin Medical approved a 1-for-20 reverse share split reducing Class A outstanding shares from 136.55 million to 6.83 million and Class B shares from 20 million to 1 million. It sets US$50,000 authorized capital into 45 million Class A and 5 million Class B shares to maintain Nasdaq listing compliance.
1. Share Combination Details
Jin Medical’s board approved a 1-for-20 share combination at an extraordinary general meeting, effective March 16, 2026, at 9:00 a.m. Eastern Time. At the effective time, every 20 existing ordinary shares consolidate into one share, reducing Class A shares from 136,547,100 to 6,827,355 and Class B shares from 20,000,000 to 1,000,000.
2. Capital Reclassification
The company reclassified its authorized share capital to US$50,000 divided into 45,000,000 Class A ordinary shares and 5,000,000 Class B ordinary shares, each with a par value of US$0.001. This dual-class structure and new CUSIP for Class A shares will be reflected in filings with the Cayman Islands Registrar of Companies.
3. Strategic Rationale and Impact
The reverse split and reclassification are intended to ensure continued compliance with Nasdaq Capital Market listing requirements and to strengthen Jin Medical’s long-term capital structure. Trading of Class A shares will commence on a consolidation-adjusted basis under the existing symbol when markets open on March 16, 2026.